Croda International (CRDA) Q1 2026 TU earnings summary

Executive summary

• Q1 2026 sales rose 1% at constant currency, matching a strong prior year quarter and aligning with guidance.

• Growth in Beauty Actives and Fragrances & Flavours offset declines in Crop Protection.

• No material impact from Middle East conflict; region represents about 5% of group sales, mainly in F&F.

• Transformation programme is progressing as planned, supporting future margin improvement and a three-year growth plan.

Financial highlights

• Q1 sales reached GBP 446 million at constant currency; reported sales were £431m, a 2% decline year-over-year.

• Consumer Care sales up 4%, led by Beauty Actives (up 12%) and F&F (up 10%).

• Life Sciences sales down 3%, mainly due to an 8% decline in Crop Protection; Seed Enhancement up 2%.

• Industrial/Industrial Specialties sales down 2% year-over-year.

Outlook and guidance

• No change to full-year 2026 guidance; sales expected to be flat between H1 and H2.

• Confident in delivering consistent sales growth, enhanced profitability, and improved returns through 2028.

• Anticipated negative FX impact of approximately £4m on FY26 operating profit if current rates persist.

• Transformation and innovation-led growth expected to drive results over the next three years.